Emerging Therapeutic Opportunities in Prostate Cancer

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, talks about new therapeutic developments going on within the prostate cancer space. 


I think we’ve got some very interesting things going on within prostate cancer. And I bring that to our attention because here in specialty pharmacy we’ve got a lot of opportunities, right. So with prostate cancer, by the time we get to see these patients many times they’re castration-resistant. We begin to see more therapies that maybe don’t have as much of a CNS side effect. So these patients we often want to make sure they’re not having types of falls or anything like that, so we’ve got some developing going on there. I think, also, opportunities around specialty generics. So we should see abiraterone go generic at some point, maybe in the next few months or year, however we see that come down.  

Most Popular

Related Articles

Although there have been links between esophageal cancer and drinking hot tea, this was the first study to examine a specific temperature.
A phase 3 study compared overall survival and cardiac safety between biosimilar trastuzumab (Ontruzant) and the reference medicine.
When combined, treatment with metformin and heme suppressed tumor growth in mice.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.